These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32492365)

  • 1. Corrigendum to: Cost-benefit analysis of enhancing the uptake of long-acting reversible contraception in Australia.
    Concepcion K; Lacey S; McGeechan K; Estoesta J; Bateson D; Botfield J
    Aust Health Rev; 2020 Jun; 44(3):501. PubMed ID: 32492365
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-benefit analysis of enhancing the uptake of long-acting reversible contraception in Australia.
    Concepcion K; Lacey S; McGeechan K; Estoesta J; Bateson D; Botfield J
    Aust Health Rev; 2020 Jun; 44(3):385-391. PubMed ID: 31655632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current barriers and potential strategies to increase the use of long-acting reversible contraception (LARC) to reduce the rate of unintended pregnancies in Australia: An expert roundtable discussion.
    Mazza D; Bateson D; Frearson M; Goldstone P; Kovacs G; Baber R
    Aust N Z J Obstet Gynaecol; 2017 Apr; 57(2):206-212. PubMed ID: 28294293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achieving cost-neutrality with long-acting reversible contraceptive methods.
    Trussell J; Hassan F; Lowin J; Law A; Filonenko A
    Contraception; 2015 Jan; 91(1):49-56. PubMed ID: 25282161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of a complex intervention in general practice to increase uptake of long-acting reversible contraceptives in Australia.
    Lewandowska M; De Abreu Lourenco R; Haas M; Watson CJ; Black KI; Taft A; Lucke J; McGeechan K; McNamee K; Peipert JF; Mazza D
    Aust Health Rev; 2021 Dec; 45(6):728-734. PubMed ID: 34903325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cost of Unintended Pregnancies in Canada: Estimating Direct Cost, Role of Imperfect Adherence, and the Potential Impact of Increased Use of Long-Acting Reversible Contraceptives.
    Black AY; Guilbert E; Hassan F; Chatziheofilou I; Lowin J; Jeddi M; Filonenko A; Trussell J
    J Obstet Gynaecol Can; 2015 Dec; 37(12):1086-97. PubMed ID: 26637081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the low uptake of long-acting reversible contraception by young women in Australia: a qualitative study.
    Garrett CC; Keogh LA; Kavanagh A; Tomnay J; Hocking JS
    BMC Womens Health; 2015 Sep; 15():72. PubMed ID: 26359250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost of unintended pregnancy in Norway: a role for long-acting reversible contraception.
    Henry N; Schlueter M; Lowin J; Lekander I; Filonenko A; Trussell J; Skjeldestad FE
    J Fam Plann Reprod Health Care; 2015 Apr; 41(2):109-15. PubMed ID: 25537792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Society for Maternal-Fetal Medicine (SMFM) Consult Series #48: Immediate postpartum long-acting reversible contraception for women at high risk for medical complications.
    ; Vricella LK; Gawron LM; Louis JM
    Am J Obstet Gynecol; 2019 May; 220(5):B2-B12. PubMed ID: 30738885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost of unintended pregnancy in Sweden - a possibility to lower costs by increasing LARC usage.
    Engstrand S; Kopp Kallner H
    Contraception; 2018 May; 97(5):445-450. PubMed ID: 29409858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing the uptake of long-acting reversible contraception in general practice: the Australian Contraceptive ChOice pRoject (ACCORd) cluster randomised controlled trial protocol.
    Mazza D; Black K; Taft A; Lucke J; McGeechan K; Haas M; McKay H; Peipert JF
    BMJ Open; 2016 Oct; 6(10):e012491. PubMed ID: 27855100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles of the pharmacist in the use of safe and highly effective long-acting reversible contraception: an opinion of the women's health practice and research network of the American College of Clinical Pharmacy.
    Rafie S; McIntosh J; Shealy KM; Borgelt LM; Forinash A; Shrader SP; Koepf ER; McClendon KS; Griffin BL; Horlen C; Karaoui LR; Rowe EL; Lodise NM; Wigle PR
    Pharmacotherapy; 2014 Sep; 34(9):991-9. PubMed ID: 24989020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors predicting uptake of long-acting reversible methods of contraception among women presenting for abortion.
    Goldstone P; Mehta YH; McGeechan K; Francis K; Black KI
    Med J Aust; 2014 Oct; 201(7):412-6. PubMed ID: 25296065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opportunity, satisfaction, and regret: Trying long-acting reversible contraception in a unique scientific circumstance.
    Burke HM; Packer CA; Spector HL; Hubacher D
    Women Health; 2019 Mar; 59(3):266-280. PubMed ID: 29920171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Not seeking yet trying long-acting reversible contraception: a 24-month randomized trial on continuation, unintended pregnancy and satisfaction.
    Hubacher D; Spector H; Monteith C; Chen PL
    Contraception; 2018 Jun; 97(6):524-532. PubMed ID: 29470950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canadian Contraception Consensus (Part 2 of 4).
    Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N
    J Obstet Gynaecol Can; 2015 Nov; 37(11):1033-9. PubMed ID: 26629725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canadian Contraception Consensus (Part 1 of 4).
    Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N;
    J Obstet Gynaecol Can; 2015 Oct; 37(10):936-42. PubMed ID: 26606712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current contraceptive use in women with a history of unintended pregnancies: Insights from the Australian Contraceptive ChOice pRoject (ACCORd) trial.
    Subasinghe AK; Watson CJ; Black KI; Taft A; Lucke J; McGeechan K; Haas M; McNamee K; Peipert JF; Mazza D
    Aust J Gen Pract; 2021 Jun; 50(6):422-425. PubMed ID: 34059848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting reversible contraceptive acceptability and unintended pregnancy among women presenting for short-acting methods: a randomized patient preference trial.
    Hubacher D; Spector H; Monteith C; Chen PL; Hart C
    Am J Obstet Gynecol; 2017 Feb; 216(2):101-109. PubMed ID: 27662799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of unintended pregnancy at 12 months between two contraceptive care programs; a controlled time-trend design.
    Madden T; Paul R; Maddipati R; Buckel C; Goodman M; Peipert JF
    Contraception; 2019 Sep; 100(3):196-201. PubMed ID: 31132346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.